Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
Pacific Biosciences of California, Inc. (PACB) Chief Financial Officer James R. Gibson II exercised options covering 500,000 shares on October 6, 2026, at an exercise price of $1.18 per share, acquiring 500,000 common shares. His reported option position afterward was 1,500,000 shares.
That day, he sold 661,815 shares at a weighted average price of $3.108 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026, and prices ranged from $3.00 to $3.33 per share.
Pacific Biosciences of California, Inc. officer Jim Gibson reported an intended sale of 661,815 common shares, with an aggregate market value of $1,899,409.05. The notice lists 500,000 shares associated with stock-option exercise and 161,815 shares associated with restricted stock units. Morgan Stanley Smith Barney LLC is identified as the broker.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported that President & CEO Mark Van Oene had 26,911 shares of common stock sold on 2026-08-17 in a transaction coded as a sale. A footnote states these shares were automatically sold to cover tax withholding obligations related to vesting restricted stock units, rather than a discretionary open-market sale. The weighted average sale price ranged from $1.13 to $1.15 per share, and Van Oene now holds 2,705,853 shares of PACB common stock directly.
ARK Investment Management LLC and Catherine D. Wood report beneficial ownership of 29,781,416 shares of Pacific Biosciences of California, Inc. common stock, representing 9.59% of the class. ARK has sole voting power over 27,781,961 shares and sole dispositive power over 29,781,416 shares, while Catherine D. Wood reports shared voting and dispositive power over these holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports that President & CEO Mark Van Oene received equity awards on August 10, 2026. He was granted a stock option for 1,967,888 shares of common stock at an exercise price of $1.15 per share, vesting in 36 equal monthly installments beginning September 10, 2026, and expiring August 10, 2036. He also received 489,130 Restricted Stock Units (RSUs), vesting in equal annual installments on August 10 of 2027, 2028, and 2029, in each case subject to continued service. Following these grants, his directly held common stock position is 2,732,764 shares.
Pacific Biosciences of California, Inc. generated $76.2 M of revenue in the first six months of 2026, roughly flat with 2025, and a gross profit of $25.5 M. Operating loss narrowed sharply to $53.0 M from $473.8 M as prior-year impairment, amortization and restructuring charges rolled off.
Cash, cash equivalents and investments were $236.9 M at June 30, 2026, down from $279.5 M at year-end after substantial operating cash outflows, partly offset by $48.1 M of net proceeds from selling short-read sequencing assets to Illumina Cambridge Limited. Convertible notes outstanding remain significant, and stockholders’ equity moved to a deficit.
The company settled patent litigation with Personal Genomics of Taiwan through a license and a $21.4 M payment obligation, and approved a July 2026 restructuring expected to cut annual operating expenses by $30–40 M via an approximately 8% workforce reduction. Mark Van Oene will become CEO on August 5, 2026 as PacBio continues emphasizing its HiFi long-read Revio and Vega platforms.
Pacific Biosciences of California, Inc. reported second-quarter 2026 revenue of $39.0 million, slightly below $39.8 million a year earlier. GAAP gross margin was 32% and non-GAAP gross margin 36%. GAAP net loss was $44.7 million, or $0.14 per share, and non-GAAP net loss was $41.9 million, or $0.14 per share. Cash, cash equivalents and investments were $236.9 million at June 30, 2026. The company expects full‑year 2026 revenue of $155 million to $165 million.
On July 30, 2026, the board approved a restructuring plan with a Reduction in Force of about 40 employees, approximately 8% of the workforce. Including related non‑headcount actions, PacBio expects to lower annualized operating expenses by $30 million to $40 million by the end of 2027 and incur about $2.0 million of pre‑tax charges, largely in the third quarter of 2026.
The board appointed Mark Van Oene as President and Chief Executive Officer and a director effective August 5, 2026, succeeding Christian Henry, who remains on the board and will serve as Senior Business Advisor through December 31, 2026. Van Oene’s employment terms include a $743,000 base salary, a target bonus equal to 100% of salary, and equity awards with grant-date values of $1,687,500 in stock options and $562,500 in RSUs. Henry’s transition agreement provides monthly salary of $12,907.62 during the transition, a potential 2026 incentive based on a $154,891.40 target, and a lump-sum payment of $1,161,685.50 subject to a separation agreement.
Pacific Biosciences of California, Inc. reported that board member Christopher M. Smith resigned from the company’s board of directors, effective immediately on July 8, 2026. The company stated it is not aware of any disagreement with Mr. Smith regarding its operations, policies, or practices that led to his resignation.
Pacific Biosciences of California director Marshall Mohr received a new stock option grant as equity compensation. The award covers 223,492 shares of common stock at an exercise price of $1.58 per share and increases his option holdings to 223,492 derivative securities.
The option vests in monthly installments over one year on the same day of the month as the grant date or, if earlier, on the date of the next annual stockholder meeting, as long as he continues serving as a director. The option expires on June 3, 2036, giving a long-dated incentive tied to the company’s share price performance.